Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2007 1
2010 2
2013 2
2015 1
2016 2
2017 3
2020 1
2022 1
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort.
Comarmond C, Pagnoux C, Khellaf M, Cordier JF, Hamidou M, Viallard JF, Maurier F, Jouneau S, Bienvenu B, Puéchal X, Aumaître O, Le Guenno G, Le Quellec A, Cevallos R, Fain O, Godeau B, Seror R, Dunogué B, Mahr A, Guilpain P, Cohen P, Aouba A, Mouthon L, Guillevin L; French Vasculitis Study Group. Comarmond C, et al. Arthritis Rheum. 2013 Jan;65(1):270-81. doi: 10.1002/art.37721. Arthritis Rheum. 2013. PMID: 23044708 Free article.
This study was undertaken to describe the main characteristics of a larger patient cohort and their long-term outcomes. METHODS: A retrospective study of EGPA patients in the French Vasculitis Study Group cohort who satisfied the American College of Rheumatology criteria a …
This study was undertaken to describe the main characteristics of a larger patient cohort and their long-term outcomes. METHODS: A re …
Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials.
Delestre F, Charles P, Karras A, Pagnoux C, Néel A, Cohen P, Aumaître O, Faguer S, Gobert P, Maurier F, Samson M, Godmer P, Bonnotte B, Cottin V, Hanrotel-Saliou C, Le Gallou T, Carron PL, Desmurs-Clavel H, Direz G, Jourde-Chiche N, Lifermann F, Martin-Silva N, Pugnet G, Quéméneur T, Matignon M, Benhamou Y, Daugas E, Lazaro E, Limal N, Ducret M, Huart A, Viallard JF, Hachulla E, Perrodeau E, Puechal X, Guillevin L, Porcher R, Terrier B; French Vasculitis Study Group (FVSG). Delestre F, et al. Ann Rheum Dis. 2024 Jan 11;83(2):233-241. doi: 10.1136/ard-2023-224623. Ann Rheum Dis. 2024. PMID: 37918894
OBJECTIVE: To compare the long-term efficacy and safety of azathioprine (AZA), 18-month fixed-schedule rituximab (RTX), 18-month tailored RTX and 36-month RTX in preventing relapses in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis who achie …
OBJECTIVE: To compare the long-term efficacy and safety of azathioprine (AZA), 18-month fixed-schedule rituximab (RTX), 18-month tail …
Embryonic environment and transgenerational effects in quail.
Leroux S, Gourichon D, Leterrier C, Labrune Y, Coustham V, Rivière S, Zerjal T, Coville JL, Morisson M, Minvielle F, Pitel F. Leroux S, et al. Among authors: riviere s. Genet Sel Evol. 2017 Jan 26;49(1):14. doi: 10.1186/s12711-017-0292-7. Genet Sel Evol. 2017. PMID: 28125975 Free PMC article.
BACKGROUND: Environmental exposures, for instance to chemicals, are known to impact plant and animal phenotypes on the long term, sometimes across several generations. Such transgenerational phenotypes were shown to be promoted by epigenetic alterations such as DNA methyla …
BACKGROUND: Environmental exposures, for instance to chemicals, are known to impact plant and animal phenotypes on the long term, som …
Long-Term Outcomes Among Participants in the WEGENT Trial of Remission-Maintenance Therapy for Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis.
Puéchal X, Pagnoux C, Perrodeau É, Hamidou M, Boffa JJ, Kyndt X, Lifermann F, Papo T, Merrien D, Smail A, Delaval P, Hanrotel-Saliou C, Imbert B, Khouatra C, Lambert M, Leské C, Ly KH, Pertuiset E, Roblot P, Ruivard M, Subra JF, Viallard JF, Terrier B, Cohen P, Mouthon L, Le Jeunne C, Ravaud P, Guillevin L; French Vasculitis Study Group. Puéchal X, et al. Arthritis Rheumatol. 2016 Mar;68(3):690-701. doi: 10.1002/art.39450. Arthritis Rheumatol. 2016. PMID: 26473755 Free article. Clinical Trial.
OBJECTIVE: Findings from the WEGENT trial and other short-term studies have suggested that azathioprine (AZA) or methotrexate (MTX) could effectively maintain remission of granulomatosis with polyangiitis (Wegener's) (GPA) or microscopic polyangiitis (MPA). This study was …
OBJECTIVE: Findings from the WEGENT trial and other short-term studies have suggested that azathioprine (AZA) or methotrexate (MTX) c …
[Incidence and presentation of the central neurological manifestations of Wegener's granulomatosis: a monocentric study of 14 cases].
Konaté A, Le Falher G, Crozat-Grosleron S, Rivière S, Le Quellec A. Konaté A, et al. Among authors: riviere s. Rev Med Interne. 2004 Mar;25(3):183-8. doi: 10.1016/S0248-8663(03)00266-2. Rev Med Interne. 2004. PMID: 14990292 Review. French.
CONCLUSIONS: Our study, based on precise criteria, indicates that the frequency of the central neurologic manifestations of Wegener's granulomatosis is probably under estimated. Cranial nerves involvement is highly evocative. The long-term prognosis seems good, in spite of …
CONCLUSIONS: Our study, based on precise criteria, indicates that the frequency of the central neurologic manifestations of Wegener's granul …
[Severe small bowel involvement and chronic intestinal pseudo-obstruction in systemic sclerosis (scleroderma): Pathophysiological, diagnostic and therapeutic basis, including parenteral nutrition].
Suzon B, Louis-Sidney F, Abel A, Moinet F, Bagoée C, Henry K, Coco-Viloin I, Cougnaud R, Wolff S, Guilpain P, Rivière S, Flori N, Deligny C, Maria A. Suzon B, et al. Among authors: riviere s. Rev Med Interne. 2024 Mar;45(3):147-155. doi: 10.1016/j.revmed.2024.02.001. Epub 2024 Feb 21. Rev Med Interne. 2024. PMID: 38388303 Review. French.
Systemic sclerosis is not an obstacle to initiation and long-term continuation of parenteral nutrition and central venous catheter implantation is not associated with an increased risk of cutaneous or infectious complications. However, continuation of long-term pare …
Systemic sclerosis is not an obstacle to initiation and long-term continuation of parenteral nutrition and central venous catheter im …
Intravenous Immunoglobulins Improve Survival in Monoclonal Gammopathy-Associated Systemic Capillary-Leak Syndrome.
Pineton de Chambrun M, Gousseff M, Mauhin W, Lega JC, Lambert M, Rivière S, Dossier A, Ruivard M, Lhote F, Blaison G, Alric L, Agard C, Saadoun D, Graveleau J, Soubrier M, Lucchini-Lecomte MJ, Christides C, Bosseray A, Levesque H, Viallard JF, Tieulie N, Lovey PY, Le Moal S, Bibes B, Malizia G, Abgueguen P, Lifermann F, Ninet J, Hatron PY, Amoura Z; EurêClark Study Group. Pineton de Chambrun M, et al. Among authors: riviere s. Am J Med. 2017 Oct;130(10):1219.e19-1219.e27. doi: 10.1016/j.amjmed.2017.05.023. Epub 2017 Jun 9. Am J Med. 2017. PMID: 28602874
This study was conducted to better describe the clinical characteristics, natural history, and long-term outcome of monoclonal gammopathy-associated systemic capillary-leak syndrome. ...
This study was conducted to better describe the clinical characteristics, natural history, and long-term outcome of monoclonal gammop …
Long-term home parenteral nutrition in systemic sclerosis-related intestinal failure is feasible but unveils occult cardiac disease.
Suzon B, Rivière S, Schiffmann A, Rivet V, Flori N, Guilpain P, Maria ATJ. Suzon B, et al. Among authors: riviere s. Nutrition. 2023 Jun;110:112009. doi: 10.1016/j.nut.2023.112009. Epub 2023 Feb 23. Nutrition. 2023. PMID: 36965242
OBJECTIVE: The aim of this study was to compare safety and efficacy of long-term home parenteral nutrition between patients with systemic sclerosis and intestinal failure (IF) and controls with IF from another etiology. ...Overloads occurred in SSc patients with and withou …
OBJECTIVE: The aim of this study was to compare safety and efficacy of long-term home parenteral nutrition between patients with syst …
Long lasting cerebellar alterations after perinatal asphyxia in rats.
Campanille V, Saraceno GE, Rivière S, Logica T, Kölliker R, Capani F, Castilla R. Campanille V, et al. Among authors: riviere s. Brain Res Bull. 2015 Jul;116:57-66. doi: 10.1016/j.brainresbull.2015.06.003. Epub 2015 Jun 24. Brain Res Bull. 2015. PMID: 26116983
In this work, we have used a murine model to induce severe global PA in rats at the time of birth. Short-term cerebellar alterations within this PA model have been previously reported but whether such alterations remain in adulthood has not been conclusively determi …
In this work, we have used a murine model to induce severe global PA in rats at the time of birth. Short-term cerebellar alter …
Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis.
Charles P, Dechartres A, Terrier B, Cohen P, Faguer S, Huart A, Hamidou M, Agard C, Bonnotte B, Samson M, Karras A, Jourde-Chiche N, Lifermann F, Gobert P, Hanrotel-Saliou C, Godmer P, Martin-Silva N, Pugnet G, Matignon M, Aumaitre O, Viallard JF, Maurier F, Meaux-Ruault N, Rivière S, Sibilia J, Puéchal X, Mouthon L, Guillevin L; French Vasculitis Study Group. Charles P, et al. Among authors: riviere s. Rheumatology (Oxford). 2020 Oct 1;59(10):2970-2975. doi: 10.1093/rheumatology/kez621. Rheumatology (Oxford). 2020. PMID: 32150263 Free article. Clinical Trial.
CONCLUSIONS: We were not able to detect a difference between the relapse-free survival rates for up to M12 for the D0 and D0+D14 rituximab-infusion groups, which could suggest that omitting the D14 rituximab remission-maintenance dose did not modify the short-term relapse- …
CONCLUSIONS: We were not able to detect a difference between the relapse-free survival rates for up to M12 for the D0 and D0+D14 rituximab-i …
18 results